Global Barrette’s Esophagus Market, by Treatment Type (GERD Medicines, Photodynamic Therapy, Radiofrequency Ablation, Endoscopic Mucosal Resection, Esophagectomy), By Treatment Providers (Hospitals, Ambulatory Surgical Center, Clinics), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.
As per the report, the growing prevalence of gastroesophageal reflux disease (GERD) and poor management of GERD are prime factors driving the growth of Barrette’s esophagus treatment market. Barrett’s esophagus is a serious complication chronic of gastroesophageal reflux disease, and its high prevalence is leaving a significant economic impact on the global healthcare system. According to US Surveillance Epidemiology and End Results (SEER), 10% of GERD patients develop Barrett’s esophagus. The low treatment rate for GERD is another major factor leading to the increased prevalence of Barrett’s esophagus. Risk factors for the development of Barrett’s disease also include obesity and tobacco smoking, but GERD is the major risk factor.
Costs due to poorly treated GERD with Barrett’s esophagus represent a substantial burden for the healthcare systems. For instance, according to a study conducted by Universitat de Barcelona and the University of Naples Italy, the estimated cost for the healthcare systems for the population with poorly treated GERD with Barrett’s esophagus was found to be €18 million in Spain, € 12 million in Germany and € 7 million in Germany, in 2015.
Furthermore, improving diagnosis rates for Barrett’s esophagus is expected to drive the market for Barrett’s esophagus over the forecast period. A study from Mayo clinic suggests that the concurrent increase number of endoscopies performed annually has improved the ability to diagnose Barrett’s esophagus.
Furthermore, Meridian Market Consultants (MMC) Study identifies that, in 2011, the population with poorly treated GERD with Barrett’s esophagus was estimated to be 29,678 in Spain, 19,327 in Germany, and 10,079 in Italy. Barrett’s esophagus is a precursor of esophageal adenocarcinoma (EAC) incidence of which has dramatically increased in the past four decades.
Although EAC is classified as rare cancer, it is the most rapidly rising cancer in the U.S. Barrett’s esophagus is primarily observed in the older adults of the developed countries such as the U.S. and European countries. Barrett's esophagus is two to three times more common in men than in women. The exact prevalence of Barrett’s esophagus in living adults is difficult to find because patients with Barrett’s esophagus are often asymptomatic. The prevalence of Barrett’s esophagus can be estimated based on findings of upper endoscopy procedures.
Treatment options for Barrett’s esophagus include medicines for GERD, endoscopic mucosal resection, photodynamic therapy, ablation therapy, and surgery, etc. Most doctors recommend periodic surveillance endoscopy with biopsy to monitor signs of cancer. Endoscopic ablation therapies use different techniques to destroy dysplasia – abnormal cells developed in the esophagus. Photodynamic therapy uses light-activated chemical and laser to destroy precancerous cells in the esophagus.
MMC Study identifies some of the key participating players in Barrett’s esophagus market globally are GlaxoSmithKline Plc., Pfizer Inc., AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Johnson and Johnson, Eisai Inc., Takeda Pharmaceuticals, etc. among others,
About Meridian Market Consultants:
Meridian Market Consultants is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.